[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627445":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"University of Rome Tor Vergata","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Vincenzo Formica, Professor","CONTACT","+390620908190","vincenzo.formica@uniroma2.it",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":19,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Tor Vergata University Hospital","RECRUITING","Rome","Italy","00133",{"type":22,"coordinates":23},"Point",[24,25],12.51133,41.89193,{"lat":25,"lon":24},[28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Vincenzo Formica","Professor","100627445",false,"NCT07448727","Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and\u002For Metastatic (R\u002FM) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET\u002FCT","Prospective Observational Study On The Impact Of Early Response To First-line Anti-PD-1 Therapy In Patients With Recurrent And\u002FOr Metastatic (R\u002FM) Head And Neck Squamous Cell Carcinoma, Assessed By 18F-FDG PET\u002FCT","PEMBRO-PET","Inclusion Criteria:\n\n* Histological diagnosis of recurrent and\u002For metastatic HNSCC, not amenable for curative locoregional treatment (either surgery or radiotherapy), and amenable for first line systemic treatment\n* CPS PD-L1 \\>=1\n\nExclusion Criteria:\n\n* Any controindication to immune checkpoint inhibitors","ALL","18 Years",{"count":43,"type":44},25,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the role of early response assessment by 18F-FDG PET\u002FCT in patients with recurrent and\u002For metastatic (R\u002FM) head and neck squamous cell carcinoma with PD-L1 CPS \\>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.",[48,49],"Head & Neck Cancer","Head & Neck Squamous Cell Carcinoma","2026-02-28",{"date":52,"type":53},"2026-03-04","ACTUAL",{"date":55,"type":53},"2024-11-20",{"date":57,"type":44},"2027-12",{"name":5,"class":6},1]